Detail akcie AEON Biopharma Rg-A online

Business Summary: AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Aeon Biopharma Inc revenues was not reported. Net loss totaled $2.1M vs. income of $39.9M. Net loss reflects Biotechnology & Medical Research segment loss totaling $7.3M vs. income of $75.3M. Basic Earnings per Share excluding Extraordinary Items decreased from $64.94 to $1.29.